Company
Siren Bio
Universal AAV Immuno-Gene Therapy for Cancer
Also known as Siren, Siren Biotechnology, SIREN BIOTECHNOLOGY, INC., Siren Care, Inc.
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Headquarters
- San Francisco, California, United States
- Employees
- 5 employees (Form C-AR)Source (opens in a new tab)
- Customers
- As a patient / As a provider
- Legal name
- SIREN BIOTECHNOLOGY, INC.
- sirenbiotechnology.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
At Siren, we are combining the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single, powerful new treatment modality to fight cancer.
Funding snapshot
- Total raised
- $19.6MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Grant, $8M2026-06-26
Funding rounds
- Grant
- $8M2026-06-26, Company stated
- Reg cf crowdfunding
- $4M2026-05-19, Company stated
- Reg cf crowdfunding
- $5M2025-04-02, SEC form C
- Round, 2025
- $9.5M2025-01-08, Company stated
- Round, 2024
- $19.6M2024-04-08, SEC form D sold, 57 investors
Products
- Hardware
- Siren Socks
- Other
- SRN-101
- Web
- SRN-101
Loading relationship preview